Business Description
AngioDynamics Inc
NAICS : 339112
SIC : 3841
ISIN : US03475V1017
Share Class Description:
ANGO: Ordinary SharesTotal Employee Number:
675Description
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Geographically operates in the USA and Other countries, maximum revenue from the USA.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.64 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.35 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.5 | |||||
3-Year EBITDA Growth Rate | -63.5 | |||||
3-Year EPS without NRI Growth Rate | -118.5 | |||||
3-Year Book Growth Rate | -24.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.43 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.43 | |||||
9-Day RSI | 56.35 | |||||
14-Day RSI | 57.99 | |||||
3-1 Month Momentum % | 8.1 | |||||
6-1 Month Momentum % | 12.34 | |||||
12-1 Month Momentum % | 34.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.19 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 0.72 | |||||
Days Inventory | 151.17 | |||||
Days Sales Outstanding | 51.04 | |||||
Days Payable | 80.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.62 | |||||
Operating Margin % | -6.97 | |||||
Net Margin % | -11.48 | |||||
EBITDA Margin % | 0.2 | |||||
FCF Margin % | 0.16 | |||||
OCF Margin % | 0.96 | |||||
ROE % | -20.82 | |||||
ROA % | -13.68 | |||||
ROIC % | -13.99 | |||||
3-Year ROIIC % | 1.57 | |||||
ROC (Joel Greenblatt) % | -30.19 | |||||
ROCE % | -11.32 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.72 | |||||
PB Ratio | 3.3 | |||||
Price-to-Tangible-Book | 5.43 | |||||
Price-to-Free-Cash-Flow | 1688.76 | |||||
Price-to-Operating-Cash-Flow | 198.71 | |||||
EV-to-EBIT | -23.23 | |||||
EV-to-EBITDA | 828.49 | |||||
EV-to-Revenue | 1.62 | |||||
EV-to-Forward-Revenue | 1.61 | |||||
EV-to-FCF | 1020.94 | |||||
Price-to-GF-Value | 1.42 | |||||
Price-to-Projected-FCF | 7.81 | |||||
Price-to-Median-PS-Value | 1.02 | |||||
| Price-to-Net-Current-Asset-Value | 8.39 | |||||
Earnings Yield (Greenblatt) % | -4.3 | |||||
FCF Yield % | 0.09 | |||||
Forward Rate of Return (Yacktman) % | 1.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANGO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AngioDynamics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 320.174 | ||
| EPS (TTM) ($) | -0.87 | ||
| Beta | 0.3684 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.46 | ||
| Volatility % | 35.11 | ||
| 14-Day RSI | 57.99 | ||
| 14-Day ATR ($) | 0.639011 | ||
| 20-Day SMA ($) | 13.08825 | ||
| 12-1 Month Momentum % | 34.32 | ||
| 52-Week Range ($) | 8.36 - 15.195 | ||
| Shares Outstanding (Mil) | 41.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AngioDynamics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AngioDynamics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2027-01-06 08:00 | In 173 days | ||
| Second quarter earnings results for 2027 | 2027-01-06 | In 172 days | ||
| First quarter earnings conference call for 2027 | 2026-10-02 08:00 | In 77 days | ||
| First quarter earnings results for 2027 | 2026-10-02 | In 76 days | ||
| General meeting for 2026 | 2026-07-23 09:00 | In 6 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-07-14 08:00 | 12.78 (-0.12%) | ||
| Annual report for 2026 | 2026-07-14 | 12.78 (-0.12%) | ||
| Fourth quarter earnings results for 2026 | 2026-07-14 | 12.78 (-0.12%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 09:20 | 12.34 (+3.26%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 08:45 | 10.24 (+5.35%) |
Show
Entries
AngioDynamics Inc Frequently Asked Questions
What is AngioDynamics Inc(ANGO)'s stock price today?
The current price of ANGO is $13.51. The 52 week high of ANGO is $15.20 and 52 week low is $8.36.
When is next earnings date of AngioDynamics Inc(ANGO)?
The next earnings date of AngioDynamics Inc(ANGO) is 2026-10-02 Est..
Does AngioDynamics Inc(ANGO) pay dividends? If so, how much?
AngioDynamics Inc(ANGO) does not pay dividend.
Guru Commentaries on NAS:ANGO
No articles.
Press Release
Articles on AngioDynamics Inc
AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
3 days ago
Headlines
See More- 1
Jul 14, 2026
AngioDynamics anticipates $336M-$341M FY 2027 net sales while targeting $13M-$16M adjusted EBITDA
Seeking Alpha • 10:00am
AngioDynamics GAAP EPS of -$0.07 beats by $0.11, revenue of $86.61M beats by $6.37M
Seeking Alpha • 5:04am
Jul 13, 2026
AngioDynamics Q4 2026 Earnings Preview
Seeking Alpha • 4:35pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers